Clinical Trial Update: Safety and Immunogenicity Study of SCB-1019T in Children [Phase 1]

View source ↗

Summary

A Phase 1 safety and immunogenicity trial of SCB-1019T for respiratory syncytial virus infection in children has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• SCB-1019T

Snippet

Sponsor: Clover Biopharmaceuticals AUS Pty | Conditions: RSV Infection | Phase 1 | Status: WITHDRAWN